Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum

The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.

Inclusion Criteria:

• An established diagnosis of pyoderma gangrenosum
• Currently experiencing an inflammatory episode of pyoderma gangrenosum
• Contraceptive measures adequate to prevent pregnancy during the study

Exclusion Criteria:

• Clinical evidence of acutely infected pyoderma gangrenosum
• History of allergic or anaphylactic reactions to monoclonal antibodies
• History of recurrent or chronic systemic infections
• Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding

Other protocol-defined inclusion/exclusion criteria may apply